BLOG — Clinical Trial

The Effect of MAF Capsules and M Capsules on Lymphopenia and Clinical Outcomes in Non-Critical Hospitalized COVID-19 PatientsPreprints with The Lancet 19 Pages Posted: 7 Feb 2023 Abstract BACKGROUND: Excessive inflammation and lymphopenia are linked to poor Covid-19 clinical outcomes. Targeting both conditions using an immunomodulating approach needs to be tested.METHODS: We conducted an open-label, randomized, controlled trial of MAF Capsules and M Capsules in adults who were hospitalized with Covid-19 and had evidence of lower respiratory tract infection but at enrolment did not require resuscitation or mechanical ventilation. Patients were randomly assigned to receive, in addition to standard of care...

We can't reveal the exact details yet, but here's a little sneak peek!  The change over time shows a clear increase in telomere length with continued MAF capsule consumption.Based on a 0-month baseline, telomere length increased by approximately 111% at 3 months and 123% at 6 months.Telomeres are crucial structures that play a significant role in cellular health and longevity. They are repetitive DNA sequences located at the ends of chromosomes, acting as protective caps to prevent the loss of important genetic information during cell division.Telomere shortening has been linked to the aging process and age-related diseases. It's often considered a...

Cytokine production of mice peritoneal macrophages   IL-1β and TNF-α are major inflammatory cytokines associated with autoimmune diseases.Our Oral MAF does not result in the production of these pro-inflammatory cytokines.   Th2 cytokinesColostrum MAF experiments in healthy dogs   This experiment was conducted by Dr Osaki at Tottori university.In this preliminary experiment, Colostrum MAF induced elevated levels of helper T cells and killer T cells in healthy dogs.   In this preliminary experiment, Colostrum MAF suppressed the production of Interleukin-4 (IL-4) and Interleukin-6 (IL-6). These Th2 cytokines are associated with allergic diseases.  

In June 2020 we applied to the COVID-19 Scientific Technical Triage of the US FDA for the evaluation of the rationale to study the efficacy of MAF Capsules in COVID-19 treatment.   In June 2020 we applied to the COVID-19 Scientific Technical Triage of the US FDA for the evaluation of the rationale to study the efficacy of MAF Capsules in COVID-19 treatment. The US FDA in PreIND 151946 meeting response recommended a small proof of concept (POC) study as the initial step prior to the large-scale trial be run. The US FDA indicated recommendations including the major study endpoints addressing the...